Study analysis · Diabetes · 2006
In 10 healthy men, a brief spike in blood sugar shrank the protective gel lining their blood vessels by about half—but an antioxidant stopped it.
When researchers temporarily raised blood sugar in 10 healthy men, the volume of the endothelial glycocalyx—a gel layer protecting blood vessels—fell by about 0.9 L (about 53% lower relative volume), and N-acetylcysteine largely prevented that drop.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a controlled experiment where scientists changed blood sugar levels in 10 healthy men and watched what happened to their blood vessels. Because they randomly ordered the tests, they can be fairly confident that high blood sugar caused the immediate changes, but the study is very small and only in healthy men, so we can't say it applies to everyone or to long-term health.
What’s the bottom line?
In 10 healthy men, researchers briefly raised blood sugar. This shrank the protective gel layer inside blood vessels and made blood more likely to clot. An antioxidant called NAC stopped much of the shrinkage, while a salt solution called mannitol did not.
How strong is this study?
The study was well-controlled because each person was compared to themselves, which reduces differences between people. But it only had 10 people, and we don't know if the researchers knew which treatment was which, so the results might be less reliable. This means the findings are interesting but need to be confirmed in larger, better-blinded studies.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
45 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=10)+1.0/20
- Follow-upno follow-up reported
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Randomized crossover design allows causal inference for acute effects in this controlled setting, but small sample (n=10), unknown blinding, and surrogate outcomes limit certainty and generalizability. Abstract-only data prevents full assessment.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information is provided in the text, so potential conflicts cannot be assessed.
The provided text is only an abstract and does not include a conflict of interest or funding section. No author affiliations or disclosure statements are available, so conflicts of interest cannot be determined.
Key takeaways
- 01
Glycocalyx volume dropped from about 1.7 L to about 0.8 L during high blood sugar—an absolute drop of about 0.9 L (about 53% lower relative volume).
- 02
With NAC, it stayed around 1.4 L.
- 03
Mannitol left it at about 1.6 L.
- 04
High blood sugar also raised hyaluronan from about 70 to 112 ng/ml (absolute +42 ng/ml; about 60% higher relative), clotting marker F1+2 from about 0.4 to 1.1 nmol/l (absolute +0.7 nmol/l; about 175% higher relative), and d-dimer from about 0.27 to 0.55 g/l (absolute +0.28 g/l; about 104% higher relative).
- 05
This was a short, small laboratory study in healthy men, not a study of long-term clinical events.
- 06
The protective layer shrank by about half its volume during high blood sugar and clotting markers rose, but whether this translates into heart attacks or strokes in people cannot be determined from this abstract.
- 07
The absolute risk of clinical events was not reported in this study.
Why this study matters
Acute hyperglycemia rapidly shrank the glycocalyx
In 10 healthy men, systemic glycocalyx volume was 1.7 ± 0.2 L during control. During normoinsulinemic hyperglycemia it fell to 0.8 ± 0.2 L (P < 0.05). That is an absolute reduction of about 0.9 L, or roughly 53% lower relative volume.
This suggests even short-term high blood sugar may damage the protective lining of blood vessels, not just long-term diabetes.
NAC prevented the shrinkage, but mannitol did not
N-acetylcysteine (NAC) infusion during hyperglycemia kept glycocalyx volume at 1.4 ± 0.2 L compared with 0.8 ± 0.2 L during hyperglycemia alone. Mannitol, an osmotic control, had no effect (1.6 ± 0.1 L).
This points to oxidative stress rather than simple osmolarity as a possible mechanism, and raises the question of whether antioxidants could protect vessels.
Blood sugar spike also activated clotting markers
Hyperglycemia increased plasma hyaluronan from 70 ± 6 to 112 ± 16 ng/ml (absolute +42 ng/ml; about 60% higher relative), prothrombin activation fragment 1+2 from 0.4 ± 0.1 to 1.1 ± 0.2 nmol/l (absolute +0.7 nmol/l; about 175% higher relative), and d-dimer from 0.27 ± 0.1 to 0.55 ± 0.2 g/l (absolute +0.28 g/l; about 104% higher relative; P < 0.05).
It links a short period of high blood sugar to measurable changes in clotting and vessel function, which could matter for cardiovascular risk.
Tiny study, big caveats
The study included only 10 healthy male subjects, used acute surrogate outcomes, and reported no clinical events such as heart attacks or strokes. Full methodology and long-term risk data are not available in the abstract.
It is a useful reminder that promising lab findings often do not translate directly into clinical advice.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In 10 healthy men, researchers briefly raised blood sugar. This shrank the protective gel layer inside blood vessels and made blood more likely to clot. An antioxidant called NAC stopped much of the shrinkage, while a salt solution called mannitol did not.
Research results
Glycocalyx volume dropped from about 1.7 L to about 0.8 L during high blood sugar—an absolute drop of about 0.9 L (about 53% lower relative volume). With NAC, it stayed around 1.4 L. Mannitol left it at about 1.6 L. High blood sugar also raised hyaluronan from about 70 to 112 ng/ml (absolute +42 ng/ml; about 60% higher relative), clotting marker F1+2 from about 0.4 to 1.1 nmol/l (absolute +0.7 nmol/l; about 175% higher relative), and d-dimer from about 0.27 to 0.55 g/l (absolute +0.28 g/l; about 104% higher relative).
What this means - more context
This was a short, small laboratory study in healthy men, not a study of long-term clinical events. The protective layer shrank by about half its volume during high blood sugar and clotting markers rose, but whether this translates into heart attacks or strokes in people cannot be determined from this abstract. The absolute risk of clinical events was not reported in this study.
To evaluate whether acute normoinsulinemic hyperglycemia affects the endothelial glycocalyx, thereby increasing vascular vulnerability.
In 10 healthy men, acute normoinsulinemic hyperglycemia reduced systemic glycocalyx volume from 1.7±0.2 L to 0.8±0.2 L (absolute reduction ~0.9 L; relative reduction ~53%; P<0.05). N-acetylcysteine (NAC) prevented the reduction (1.4±0.2 L), while mannitol had no effect (1.6±0.1 L). Hyperglycemia also caused endothelial dysfunction and increased plasma hyaluronan and coagulation activation markers.
Methods Used
In 10 healthy male subjects, systemic glycocalyx volume was estimated by comparing the distribution volume of a glycocalyx-permeable tracer (dextran 40) with that of a glycocalyx-impermeable tracer (labeled erythrocytes). Measurements were performed in random order on five occasions: two control measurements, two during normoinsulinemic hyperglycemia with or without NAC infusion, and one during mannitol infusion. Methodology details beyond the abstract are not available.
Main Finding
Acute normoinsulinemic hyperglycemia reduced systemic glycocalyx volume from 1.7±0.2 L to 0.8±0.2 L (absolute reduction ~0.9 L; relative reduction ~53%; P<0.05). NAC prevented the reduction (1.4±0.2 L), while mannitol had no effect (1.6±0.1 L). Hyperglycemia caused endothelial dysfunction, increased plasma hyaluronan from 70±6 to 112±16 ng/ml (absolute increase +42 ng/ml; relative increase ~60%; P<0.05), and activated coagulation (prothrombin activation fragment 1+2: 0.4±0.1 to 1.1±0.2 nmol/l, absolute increase +0.7 nmol/l, relative increase ~175%; d-dimer: 0.27±0.1 to 0.55±0.2 g/l, absolute increase +0.28 g/l, relative increase ~104%; P<0.05). No absolute risk of clinical events was reported.
Confidence Level
Limited - based on abstract only; full methodology, randomization details, blinding, allocation concealment, and statistical analysis are not available. Small sample (n=10 healthy men) and acute surrogate outcomes further limit certainty.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Very small sample (10 healthy male subjects) limits generalizability
- •Acute surrogate outcomes; no clinical event or long-term risk data reported
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study is like a controlled experiment where scientists changed blood sugar levels in 10 healthy men and watched what happened to their blood vessels. Because they randomly ordered the tests, they can be fairly confident that high blood sugar caused the immediate changes, but the study is very small and only in healthy men, so we can't say it applies to everyone or to long-term health.
Strengths
- Randomized crossover design with within-subject controls
- Multiple control conditions (normoglycemia, mannitol)
- Reproducible glycocalyx measurements
Weaknesses
- Small sample size (n=10)
- Blinding unknown
- Full methodology not available - based on abstract only
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In 10 healthy men, researchers briefly raised blood sugar. This shrank the protective gel layer inside blood vessels and made blood more likely to clot. An antioxidant called NAC stopped much of the shrinkage, while a salt solution called mannitol did not.
Research results
Glycocalyx volume dropped from about 1.7 L to about 0.8 L during high blood sugar—an absolute drop of about 0.9 L (about 53% lower relative volume). With NAC, it stayed around 1.4 L. Mannitol left it at about 1.6 L. High blood sugar also raised hyaluronan from about 70 to 112 ng/ml (absolute +42 ng/ml; about 60% higher relative), clotting marker F1+2 from about 0.4 to 1.1 nmol/l (absolute +0.7 nmol/l; about 175% higher relative), and d-dimer from about 0.27 to 0.55 g/l (absolute +0.28 g/l; about 104% higher relative).
What this means - more context
This was a short, small laboratory study in healthy men, not a study of long-term clinical events. The protective layer shrank by about half its volume during high blood sugar and clotting markers rose, but whether this translates into heart attacks or strokes in people cannot be determined from this abstract. The absolute risk of clinical events was not reported in this study.
To evaluate whether acute normoinsulinemic hyperglycemia affects the endothelial glycocalyx, thereby increasing vascular vulnerability.
In 10 healthy men, acute normoinsulinemic hyperglycemia reduced systemic glycocalyx volume from 1.7±0.2 L to 0.8±0.2 L (absolute reduction ~0.9 L; relative reduction ~53%; P<0.05). N-acetylcysteine (NAC) prevented the reduction (1.4±0.2 L), while mannitol had no effect (1.6±0.1 L). Hyperglycemia also caused endothelial dysfunction and increased plasma hyaluronan and coagulation activation markers.
Methods Used
In 10 healthy male subjects, systemic glycocalyx volume was estimated by comparing the distribution volume of a glycocalyx-permeable tracer (dextran 40) with that of a glycocalyx-impermeable tracer (labeled erythrocytes). Measurements were performed in random order on five occasions: two control measurements, two during normoinsulinemic hyperglycemia with or without NAC infusion, and one during mannitol infusion. Methodology details beyond the abstract are not available.
Main Finding
Acute normoinsulinemic hyperglycemia reduced systemic glycocalyx volume from 1.7±0.2 L to 0.8±0.2 L (absolute reduction ~0.9 L; relative reduction ~53%; P<0.05). NAC prevented the reduction (1.4±0.2 L), while mannitol had no effect (1.6±0.1 L). Hyperglycemia caused endothelial dysfunction, increased plasma hyaluronan from 70±6 to 112±16 ng/ml (absolute increase +42 ng/ml; relative increase ~60%; P<0.05), and activated coagulation (prothrombin activation fragment 1+2: 0.4±0.1 to 1.1±0.2 nmol/l, absolute increase +0.7 nmol/l, relative increase ~175%; d-dimer: 0.27±0.1 to 0.55±0.2 g/l, absolute increase +0.28 g/l, relative increase ~104%; P<0.05). No absolute risk of clinical events was reported.
Confidence Level
Limited - based on abstract only; full methodology, randomization details, blinding, allocation concealment, and statistical analysis are not available. Small sample (n=10 healthy men) and acute surrogate outcomes further limit certainty.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Very small sample (10 healthy male subjects) limits generalizability
- •Acute surrogate outcomes; no clinical event or long-term risk data reported
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study is like a controlled experiment where scientists changed blood sugar levels in 10 healthy men and watched what happened to their blood vessels. Because they randomly ordered the tests, they can be fairly confident that high blood sugar caused the immediate changes, but the study is very small and only in healthy men, so we can't say it applies to everyone or to long-term health.
Strengths
- Randomized crossover design with within-subject controls
- Multiple control conditions (normoglycemia, mannitol)
- Reproducible glycocalyx measurements
Weaknesses
- Small sample size (n=10)
- Blinding unknown
- Full methodology not available - based on abstract only
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study was well-controlled because each person was compared to themselves, which reduces differences between people. But it only had 10 people, and we don't know if the researchers knew which treatment was which, so the results might be less reliable. This means the findings are interesting but need to be confirmed in larger, better-blinded studies.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
45 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=10)+1.0/20
- Follow-upno follow-up reported
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Randomized crossover design allows causal inference for acute effects in this controlled setting, but small sample (n=10), unknown blinding, and surrogate outcomes limit certainty and generalizability. Abstract-only data prevents full assessment.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information is provided in the text, so potential conflicts cannot be assessed.
The provided text is only an abstract and does not include a conflict of interest or funding section. No author affiliations or disclosure statements are available, so conflicts of interest cannot be determined.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Siim Land cite this study, drawing 1 claim from it.
- Strong evidence
At least some randomized or controlled trials support this claim.
Evidence
Authored by
12 researchersIf this is your work, this is how we attribute it on Fit Body Science. Max Nieuwdorp is listed as the lead author.
- Amsterdam UMC Location University of Amsterdam
Cited in 1 claim